MRI of focal liver lesions

Current Medical Imaging Reviews

Volumn 8, Issue 2, 2012, Pages 107-116

  Albiin, Nils ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diagnosis; Diffusion weighted magnetic resonance imaging; HCC; Hepatocellular carcinoma; Liver metastases; Liver neoplasms; Magnetic resonance imaging; MRI; Radiology; Review

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOXETIC ACID;

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTADENOCARCINOMA; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FATTY LIVER; HUMAN; INTERMETHOD COMPARISON; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER CYST; LIVER HEMANGIOMA; LIVER HYDATID CYST; LIVER HYPERPLASIA; LIVER INJURY; LIVER METASTASIS; LIVER NODULE; LYMPHOMA; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ULTRASOUND;

EID: 84861786675     PISSN: 15734056     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340512800672216     Document Type: Review

References (68)

1. Bruegel M, Rummeny EJ. Hepatic metastases: use of diffusionweighted echo-planar imaging. Abdom Imaging 2010; 35(4): 454-61.
2. Matsui O, Kadoya M, Kameyama T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989; 173(1): 123-6.
3. Merkle EM, Nelson RC. Dual gradient-echo in-phase and opposedphase hepatic MR imaging: a useful tool for evaluating more than fatty infiltration or fatty sparing. Radiographics 2006; 26(5): 1409-18.
4. Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging 2010.
5. Kilickesmez O, Bayramoglu S, Inci E, Cimilli T. Value of apparent diffusion coefficient measurement for discrimination of focal benign and malignant hepatic masses. J Med Imaging Radiat Oncol 2009; 53(1): 50-5.
6. Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM. The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol 2009; 16(10): 1208-14.
7. Miller FH, Hammond N, Siddiqi AJ, et al. Utility of diffusionweighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging 2010; 32(1): 138-47.
8. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intraand interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006; 24(6): 1378-85.
9. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003; 38(2): 85-94.
10. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14(4): 559-78.
11. Dahlstrom N, Persson A, Albiin N, Smedby O, Brismar TB. Contrast-enhanced magnetic resonance cholangiography with GdBOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol 2007; 48(4): 362-8.
12. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009; 29(6): 1323-31.
13. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. Liver vessel enhancement by Gd-BOPTA and Gd-EOBDTPA: a comparison in healthy volunteers. Acta Radiol 2009; 50(7): 709-15.
14. Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 2009; 29(3): 636-40.
15. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29(6): 1725-48.
16. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 2009; 44(6): 305-10.
17. Nakamura Y, Ohmoto T, Saito T, Kajima T, Nishimaru E, Ito K. Effects of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on T2-weighted MRCP. Magn Reson Med Sci 2009; 8(4): 143-8.
18. Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW. Diffusionweighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2010; 20(5): 1052-60.
19. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218(1): 27-38.
20. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96(2): 189-95.
21. Yu JS, Kim JH, Chung JJ, Kim KW. Added value of diffusionweighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging 2009; 30(1): 153-60.
22. Yuan Z, Ye XD, Dong S, et al. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 2010; 75(1): e9-14.
23. Van Persijn van Meerten, EL. Gelderblom H, Bloem JL RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2009.
24. Anderson SW, Kruskal JB, Kane RA. Benign hepatic tumors and iatrogenic pseudotumors. Radiographics 2009; 29(1): 211-29.
25. Federle MP G-CS, Anne VS et al. Hepatobiliary and Pancreas. In: MP F, editor. Diagnostic Imaging Abdomen. Salt Lake City: Amirsys Inc.; 2005; p. 1-149.
26. Sasaki K, Ito K, Fujita T, et al. Small hepatic lesions found on single-phase helical CT in patients with malignancy: diagnostic capability of breath-hold, multisection fluid-attenuated inversionrecovery (FLAIR) MR imaging using a half-fourier acquisition single-shot turbo spin-echo (HASTE) sequence. J Magn Reson Imaging 2007; 25(1): 129-36.
27. Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000; 118(3): 560-4.
28. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236(1): 166-77.
29. Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S. Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium. J Magn Reson Imaging 2010; 32(2): 341-4.
30. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008; 43(7): 504-11.
31. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int 2008; 2(3): 316-21.
32. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992; 183(3): 819-25.
33. Shinmura R, Matsui O, Kobayashi S, et al. Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 2005; 237(2): 512-9.
34. Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 2005; 237(3): 938-44.
35. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 2010; 34(4): 506-12.
36. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40(3): 225-35.
37. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59(5): 638-44.
38. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35(3): 421-30.
39. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.
40. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. AASLD PRACTICE GUIDELINE. Hepatology 2010.
41. Lencioni R, Crocetti L, Della Pina MC, Cioni D. Guidelines for imaging focal lesions in liver cirrhosis. Expert Rev Gastroenterol Hepatol 2008; 2(5): 697-703.
42. Iavarone M, Sangiovanni A, Forzenigo LV, et al. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell differentiation. Hepatology 2010; 52(5): 1723-30.
43. Yu NC, Chaudhari V, Raman SS, et al. Computed Tomography and Magnetic Resonance Imaging Improve Detection of Hepatocellular Carcinoma, Compared With Ultrasound Alone, in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2010.
44. Golfieri R, Marini E, Bazzocchi A, et al. Small (
45. Kim SH, Choi BI, Lee JY, et al. Diagnostic accuracy of multi/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the milan criteria before liver transplantation. Intervirology 2008; 51 Suppl 1:52-60.
46. Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol 2010; 194(5): W396-400.
47. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105(3): 599-609.
48. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 2009; 27(2): 114-24.
49. Kim SH, Lee J, Kim MJ, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192(6): 1675-81.
50. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008; 191(2): 529-36.
51. Nishie A, Yoshimitsu K, Asayama Y, et al. Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol 2008; 190(1): 81-7.
52. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadoliniumenhanced gradient-echo images. AJR Am J Roentgenol 1998; 170(4): 1005-13.
53. Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006; 239(2): 438-47.
54. Golfieri R, Marini E, Bazzocchi A, et al. Small (
55. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45(2): 96-103.
56. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced threedimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005; 15(2): 220-8.
57. Xu PJ, Yan FH, Wang JH, Lin J, Ji Y. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. J Magn Reson Imaging 2009; 29(2): 341-9.
58. Corrigan K, Semelka RC. Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging 1995; 20(2): 122-5.
59. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51(6): 2020-9.
60. Albiin N, Smith IC, Arnelo U, et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol 2008; 49(8): 855-62.
61. Uetsuji S, Yamamura M, Yamamichi K, Okuda Y, Takada H, Hioki K. Absence of colorectal cancer metastasis to the cirrhotic liver. Am J Surg 1992; 164(2): 176-7.
62. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--metaanalysis. Radiology 2005; 237(1): 123-31.
63. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010; 20(11): 2690-8.
64. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusionweighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239(1): 122-30.
65. Namasivayam S, Salman K, Mittal PK, Martin D, Small WC. Hypervascular hepatic focal lesions: spectrum of imaging features. Curr Probl Diagn Radiol 2007; 36(3): 107-23.
66. Gazelle GS, Lee MJ, Hahn PF, Goldberg MA, Rafaat N, Mueller PR. US, CT, and MRI of primary and secondary liver lymphoma. J Comput Assist Tomogr 1994; 18(3): 412-5.
67. Beaty SD, Silva AC, Depetris G. AJR teaching file: incidental hepatic mass. AJR Am J Roentgenol 2008; 190(6 Suppl): S62-4.
68. Chan JH, Tsui EY, Luk SH, et al. Diffusion-weighted MR imaging of the liver: distinguishing hepatic abscess from cystic or necrotic tumor. Abdom Imaging 2001; 26(2): 161-5.